We consider that these findings add evidence to the role that polymorphisms C360T and C201T of the dCK gene and A79C of the CDA gene have to anticipate toxicities and predict treatment outcome and toxicity in patients with AML treated with cytarabine-based chemotherapy. The gene discussed is CDA; the disease is acute myeloid leukemia.